Incyte Corporation (INCY)
NASDAQ: INCY · IEX Real-Time Price · USD
65.30
+1.30 (2.03%)
At close: Jul 17, 2024, 4:00 PM
65.31
+0.01 (0.02%)
After-hours: Jul 17, 2024, 6:08 PM EDT

Company Description

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally.

The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.

Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors.

The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460.

It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib.

The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers.

The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003.

Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Incyte Corporation
Incyte logo
Country United States
Founded 1991
IPO Date Nov 4, 1993
Industry Biotechnology
Sector Healthcare
Employees 2,524
CEO Herve Hoppenot

Contact Details

Address:
1801 Augustine Cut-off
Wilmington, Delaware 19803
United States
Phone (302) 498-6700
Website incyte.com

Stock Details

Ticker Symbol INCY
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000879169
CUSIP Number 45337C102
ISIN Number US45337C1027
Employer ID 94-3136539
SIC Code 8731

Key Executives

Name Position
Herve Hoppenot Chief Executive Officer and Chairman
Christiana Stamoulis MBA Executive Vice President and Chief Financial Officer
Dr. Barry P. Flannelly M.B.A., Pharm.D. Executive Vice President and GM of North America
Dr. Steven H. Stein M.D. Executive Vice President and Chief Medical Officer
Dr. Pablo J. Cagnoni M.D., Ph.D. President and Head of Research and Development
Thomas Tray Vice President of Finance, Chief Accounting Officer and Controller
Michael James Morrissey Executive Vice President and Head of Global Technical Operations
Sheila A. Denton Executive Vice President, General Counsel and Corporate Secretary
Pamela M. Murphy Vice President of Investor Relations and Corporate Communications
Paula J. Swain Executive Vice President of Human Resources

Latest SEC Filings

Date Type Title
Jul 16, 2024 144 Filing
Jul 9, 2024 144 Filing
Jul 3, 2024 8-K Current Report
Jun 14, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Jun 14, 2024 8-K Current Report
Jun 13, 2024 SC TO-I/A Filing
Jun 12, 2024 144 Filing
Jun 11, 2024 SC TO-I/A Filing
Jun 6, 2024 144 Filing
Jun 4, 2024 SC TO-I/A Filing